H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)

September 4, 2026 6:46 AM

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $8.00 price target on Milestone Pharmaceuticals (NASDAQ: MIST).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found